HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR - Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company's stock.

Separately, Needham & Company LLC restated a buy rating and set a $8.00 target price on shares of Esperion Therapeutics in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of $9.33.

Esperion Therapeutics Stock Down 13.9 %

NASDAQ:ESPR traded down $0.33 on Wednesday, reaching $2.04. 13,723,144 shares of the company's stock traded hands, compared to its average volume of 7,041,883. The stock has a 50-day simple moving average of $2.31 and a 200-day simple moving average of $2.07. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40. The firm has a market cap of $386.38 million, a PE ratio of -0.96 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same period last year, the business posted ($0.76) EPS. On average, equities analysts anticipate that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Institutional Trading of Esperion Therapeutics

A number of large investors have recently modified their holdings of ESPR. Spire Wealth Management raised its holdings in shares of Esperion Therapeutics by 69.2% in the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC bought a new position in Esperion Therapeutics in the fourth quarter worth approximately $30,000. Herbst Group LLC purchased a new stake in Esperion Therapeutics during the first quarter worth $28,000. Summit Financial LLC lifted its holdings in Esperion Therapeutics by 66.8% during the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 10,355 shares during the period. Finally, PSI Advisors LLC boosted its position in Esperion Therapeutics by 161.5% during the 4th quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company's stock valued at $51,000 after acquiring an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.